🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  2. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  3. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  4. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  6. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  7. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  8. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  9. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  10. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  11. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  12. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  13. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  14. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  15. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  16. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  17. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  18. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  19. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  20. Alirocumab

    Regeneron UK Limited

    Coronary Vessel

    phase 3 small molecule completed

    1 trial

  21. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  22. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  23. Alirocumab 150 MG/ML [Praluent]

    Regeneron UK Limited

    Hemodialysis

    phase 3 small molecule active

    1 trial

  24. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources